News from csl behring A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 09, 2017, 09:55 ET AFSTYLA®, for Haemophilia A, Receives European Commission Approval

Global biotherapeutics leader CSL Behring announced today that the European Commission has granted marketing authorisation for AFSTYLA® [Recombinant...


Dec 22, 2016, 10:00 ET CSL CEO Says Holistic Approach to Business is Essential to Corporate Sustainability, the Company's Value Chain and Patients

CSL Limited (ASX: CSL), parent company of CSL Behring, has recorded another strong performance in corporate responsibility, outlining in its 2015/16...


Dec 14, 2016, 01:58 ET Health Canada Approves CSL Behring's AFSTYLA™ for the Treatment of Hemophilia A

Global biotherapeutics leader CSL Behring announced that Health Canada has approved AFSTYLA [Antihemophilic Factor VIII (Recombinant), SingleChain],...


Dec 03, 2016, 08:30 ET CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting

Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION®...


Nov 15, 2016, 01:25 ET CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial

CSL Behring today announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein...


Nov 14, 2016, 10:00 ET AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use...


Oct 27, 2016, 02:30 ET CSL Behring Receives 2016 Marcum Innovator Breakthrough Award for Pioneering New Advancements in the Biotech/Healthcare Field

Marcum LLP and Philadelphia SmartCEO magazine have recognized CSL Behring with the 2016 Innovator Breakthrough Award for developing novel products...


Oct 07, 2016, 03:00 ET Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma

More than 1,000 plasma donations may be needed to treat one adult patient with a rare disease for a year During International Plasma Awareness Week,...


Sep 29, 2016, 09:46 ET Japan's Ministry of Health, Labour and Welfare (MHLW) Approves CSL Behring's IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals

Global biotherapeutics leader CSL Behring announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved IDELVION®...


Aug 30, 2016, 09:00 ET FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's Biologics License Application...


Jul 27, 2016, 10:00 ET CSL Behring Presents Pivotal Efficacy Data for AFSTYLA® In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress

CSL Behring today presented data from a Phase III pivotal study of AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] in hemophilia A...


Jul 26, 2016, 10:00 ET CSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at the World Federation of Hemophilia 2016 World Congress

CSL Behring today announced new data from its Phase III PROLONG-9FP clinical development program evaluating IDELVION® [Coagulation Factor IX...


Jul 25, 2016, 11:00 ET CSL Behring Awards Emerging Coagulation Specialists Across the Globe to Support Advancements in the Care of Patients with Bleeding Disorders

CSL Behring today announced that the company has named five recipients of the 2016 CSL Behring Professor Heimburger Award for coagulation research at ...


Jul 19, 2016, 10:00 ET CSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress

CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the XXXII International...


Jul 18, 2016, 11:55 ET U.S. FDA Approves CSL Behring's Berinert® as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE)

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert [C1 Esterase Inhibitor (Human)], its...


Jun 23, 2016, 05:30 ET CSL Behring Announces Immunoglobulin Research Grant Winners

CSL Behring announced today at the Peripheral Nerve Society's Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow,...


Jun 20, 2016, 09:00 ET AFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A - Now Available in the U.S.

Driven by its promise to save lives, CSL Behring announced today that AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel...


May 26, 2016, 03:20 ET U.S. FDA Approves CSL Behring's AFSTYLA® -- The First and Only Recombinant Factor VIII Single Chain Therapy for Hemophilia A

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved AFSTYLA® [Antihemophilic Factor (Recombinant), Single...


May 13, 2016, 10:15 ET CSL's Paul Perreault Receives Healthcare CEO Enterprise Award from Philadelphia Alliance for Capital and Technologies

Philadelphia Alliance for Capital and Technologies (PACT), an affiliate of the Greater Philadelphia Chamber of Commerce, has recognized CSL CEO and...


May 11, 2016, 11:00 ET European Commission Approves IDELVION® --CSL Behring's Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals

CSL Behring announced today that the European Commission has approved IDELVION® [albutrepenonacog alfa], its innovative, long-acting albumin fusion...


May 11, 2016, 01:30 ET IDELVION® -- CSL Behring's Innovative Therapy for Hemophilia B Patients -- Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug Administration

CSL Behring announced today it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration (FDA) for IDELVION®...


Apr 25, 2016, 09:00 ET CSL Behring Commemorates 100 Years of Delivering on its Promise to Develop Innovative Therapies for People with Life-threatening Medical Conditions

CSL Behring today commemorated 100 years of developing and delivering innovative therapies to treat people with life-threatening medical conditions...


Apr 13, 2016, 09:12 ET CSL Behring Marks World Hemophilia Day by Donating IUs of Its Specialty Biotherapeutics for Bleeding Disorders to World Federation of Hemophilia

"Treatment for All is the Vision for All" is the World Federation of Hemophilia's (WFH) global message for World Hemophilia Day this year (April 17,...


Mar 21, 2016, 09:18 ET IDELVION® for Hemophilia B Now Available in the U.S.

CSL Behring announced today that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting recombinant albumin...


Mar 15, 2016, 09:30 ET CSL Behring sponsors IDF webinar series for young adults living with primary immunodeficiencies

In honor of the upcoming World Primary Immunodeficiencies (PI) Week, CSL Behring is proud to sponsor Immune Deficiency Foundation's new PI Voices,...